2020-09-25 10:00
Biovica, active in blood-based cancer diagnostics, today announced that the company has filed a 510(k) submission with the U.S. Food and Drug Administration (FDA). “The 510(k) submission is a major step towards bringing DiviTum®TKa to patients...
2020-08-27 17:10
The following resolutions were passed at the annual general meeting of Biovica AB (publ) on 27 August 2020 in Uppsala. Adoption of the accounts for the financial year 2019/2020 and discharge from liability The annual general meeting, AGM, resolved to...
2020-08-27 08:00
Clinical validation completed, work with the FDA submission in the final phase Significant events during the fourth quarter Significant events after the end of the period CEO’s comments During the quarter, we took important steps towards achieving...
2020-08-26 23:30
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE...
2020-08-26 17:34
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE...
2020-08-26 17:30
Biovica today announces that the clinical validation of the blood test DiviTum® TKa has been completed, demonstrating the clinical value of the product. The clinical validation is the final part of Biovica’s application for US market approval...
2020-07-22 08:00
The Board of Directors of Biovica International AB, corporate identity number 556774-6150, hereby convenes the Annual General Meeting on 27 August 2020 at 16:00 in the company's premises at Dag Hammarskjölds väg 54B, Uppsala Science Park...
2020-06-30 08:00
Biovica’s annual report for the fiscal year 2019/2020 is published on our website https://biovica.com/investor-relations/financials/ Contact Anders Rylander, CEO Phone: +46-18-444 48 35 E-mail: anders.rylander@biovica.com Cecilia Driving, EVP CFO/HR/IR...
2020-06-17 08:00
Biovica, active in cancer diagnostics, today announced that the analytical validation of the blood test DiviTum has been completed. The validation aims to verify technical and precision requirements defined in consultation with the US Food and Drug Administration...
2020-06-05 08:00
Preparations for the launch of DiviTum® have started Significant events during the fourth quarter Significant events after the end of the period CEO’s comments Biovica has had yet another eventful quarter. We have focused our efforts on the...
>4,500
Numbers of patients in studies
28
Publications
32
Pharma Projects